Intranasal erythropoietin therapy in nervous system disorders

GENÇ Ş., Zadeoglulari Z., Oner M. G., Genc K., Digicaylioglu M.

EXPERT OPINION ON DRUG DELIVERY, cilt.8, sa.1, ss.19-32, 2011 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 8 Sayı: 1
  • Basım Tarihi: 2011
  • Doi Numarası: 10.1517/17425247.2011.540236
  • Dergi Adı: EXPERT OPINION ON DRUG DELIVERY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.19-32
  • Anahtar Kelimeler: blood-brain barrier, erythropoietin, nasal drug delivery, nervous system, neuroprotection, stroke, RECOMBINANT-HUMAN-ERYTHROPOIETIN, GROWTH-FACTOR-I, BLOOD-BRAIN-BARRIER, ANEURYSMAL SUBARACHNOID HEMORRHAGE, NEUROTROPHIC FACTORS, CEREBRAL-ISCHEMIA, NASAL CAVITY, DOUBLE-BLIND, DELIVERY, INSULIN
  • Dokuz Eylül Üniversitesi Adresli: Evet

Özet

Importance of the field: Erythropoietin (EPO) is a growth hormone and cytokine that plays an important role in erythropoiesis and neuroprotection. However, EPO treatment for neurological diseases requires repeated injections or high-dose systemic administration, which may cause systemic side effects. The lack of any effective treatment of acute and chronic neurodegenerative diseases and the promising outcome by EPO in animal models in vivo demand a critical evaluation of intranasal EPO delivery to the brain as an alternative administration method.